Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
News|Articles|June 17, 2025
Recap: 2025 Revolutionizing Atopic Dermatitis Conference
Catch up on all updates and advancements shared at this year's Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.
Advertisement
Advertisement
To stay informed with all conference insights,
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Advertisement
Advertisement